IE
KLRS

Israel Englander’s Kalaris Therapeutics KLRS Stock Holding History

Israel Englander’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-59,534
Closed -$344K – 6533
2026
Q1 		$344K Buy
+59,534
New +$528K ﹤0.01% 4948
2025
Q4 		– Sell
-24,923
Closed -$144K – 6594
2025
Q3 		$144K Sell
24,923
-29,169
-54% -$96.4K ﹤0.01% 5628
2025
Q2 		$144K Buy
54,092
+37,510
+226% +$169K ﹤0.01% 5453
2025
Q1 		$133K Sell
16,582
-115,322
-87% -$1.13M ﹤0.01% 5389
2024
Q4 		$1.27M Sell
131,904
-10,913
-8% -$165K ﹤0.01% 4005
2024
Q3 		$2.66M Sell
142,817
-476
-0.3% -$8.33K ﹤0.01% 3437
2024
Q2 		$2.38M Buy
143,293
+15,354
+12% +$271K ﹤0.01% 3382
2024
Q1 		$2.22M Sell
127,939
-41,801
-25% -$682K ﹤0.01% 3644
2023
Q4 		$2.65M Buy
169,740
+137,418
+425% +$5.42M ﹤0.01% 3374
2023
Q3 		$1.6M Buy
32,322
+22,986
+246% +$1.57M ﹤0.01% 3771
2023
Q2 		$730K Buy
9,336
+6,340
+212% +$603K ﹤0.01% 4278
2023
Q1 		$272K Buy
2,996
+1,827
+156% +$233K ﹤0.01% 4979
2022
Q4 		$138K Buy
+1,169
New +$198K ﹤0.01% 5476
2022
Q3 		– Sell
-762
Closed -$68K – 7584
2022
Q2 		$68K Sell
762
-5,455
-88% -$572K ﹤0.01% 6078
2022
Q1 		$965K Buy
6,217
+3,191
+105% +$637K ﹤0.01% 4568
2021
Q4 		$901K Buy
+3,026
New +$1.4M ﹤0.01% 4508
2021
Q3 		– Sell
-3,791
Closed -$1.72M – 7348
2021
Q2 		$1.72M Buy
+3,791
New +$1.96M ﹤0.01% 4142

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Israel Englander's KLRS Position: Q2 2026 in Review

Israel Englander sold out of Kalaris Therapeutics (KLRS) in Q2 2026, closing a stake of 59,534 shares — an estimated $344K sold.

Israel Englander first reported a position in KLRS in Q2 2021 and held it in 17 quarters. The position peaked at $2.66M in Q3 2024. 57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Israel Englander reported no remaining Kalaris Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 59,534 Kalaris Therapeutics shares in Q2 2026, an estimated $344K.
  • Israel Englander first reported a position in Kalaris Therapeutics in Q2 2021 and held it in 17 quarters.
  • Israel Englander's Kalaris Therapeutics position peaked at $2.66M in Q3 2024.
  • 57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.